Clinical trials: 2019 nCoV, PD-1
2019 nCoV, PD-1
Immunoregulatory Therapy for 2019-nCoV
Sepsis, including viral infections, are major causes of death worldwide. Studies show that in 2017, the number of sepsis patients worldwide reached as high as 48.9 million, of which 11 million patients died.
- Trial name
- NCT04268537
- Testing
- PD-1 blocking antibody+standard treatment, Thymosin+standard treatment, standard treatment
- Volunteers
- 120 people
- Sponsor
- Southeast University, China
COVID-19, SARS-CoV-2
COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1
This is an open-label, controlled, single-centre pilot study of nivolumab in adult patients with COVID-19. This clinical study aims to evaluate efficacy of anti-PD1 antibody in relation to viral clearance and its safety.
- Conditions
- COVID-19, SARS-CoV-2, 2019-nCoV, Pneumonia, Viral
- Trial name
- NCT04356508
- Testing
- Nivolumab
- Volunteers
- 15 people
- Sponsor
- Dr Gerry Gin Wai Kwok